No writing assistance was utilized in the production of this manuscript. Ligand-mediated EGF receptor (EGFR) targeting of nanovehicles is an effective way for cancer cell-selective delivery of ...

Fesomersen has arisen out of Ionis' LIgand-Conjugated Antisense (LICA ... in part because it produces stable oligonucleotides with a long duration of action. The Factor XI-targeting drug only ...

Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide ... field include Biogen’s ASO Spinraza (nusinersen) approved ...

The drug candidate acts by targeting transthyretin (TTR) protein. It is developed based on ligand conjugated antisense technology (LICA) platform. GlobalData, the leading provider of industry ...

Its major products include Spinraza for spinal muscular atrophy ... It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to ...

(PRNewsfoto/PANTHERx Rare) TRYNGOLZA is a GalNAc 3-conjugated antisense oligonucleotide therapy that selectively binds and degrades apoC-III mRNA to reduce hepatic production of apoC-III, a protein ...

The success of antisense oligonucleotide (ASO) therapies, such as nusinersen (Spinraza), underscores the transformative impact these molecules can have on patient outcomes. The high specificity of ...

IONIS-FB-LRx is a ligand conjugated antisense (LICA ... which led to the launch this year of Spinraza (nusinersen) for spinal muscular atrophy. In a new white paper from the World Without ...